You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluspirilene
Accession NumberDB04842
TypeSmall Molecule
GroupsApproved
DescriptionA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Structure
Thumb
Synonyms
Fluspirileno
Fluspirilenum
Imap
External Identifiers
  • Lopac-F-100
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Imap Forte Inj 10mg/mlsuspension10 mgintramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1982-12-311998-08-13Canada
Imap Inj 2mg/mlsuspension2 mgintramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1977-12-311998-03-12Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ImapJanssen
lmapMcNeil
RedeptinSKF
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIC5QA4GLR9M
CAS number1841-19-6
WeightAverage: 475.5727
Monoisotopic: 475.243519039
Chemical FormulaC29H31F2N3O
InChI KeyInChIKey=QOYHHIBFXOOADH-UHFFFAOYSA-N
InChI
InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
IUPAC Name
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
SMILES
FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylimidazolidine
  • Phenylbutylamine
  • Azaspirodecane
  • Dialkylarylamine
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Piperidine
  • Imidazolidinone
  • Aryl halide
  • Aryl fluoride
  • Imidazolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for the treatment of schizophrenia.
PharmacodynamicsFluspirilene is a relatively long-acting injectable depot antipsychotic drug used for schizophrenia. Fluspirilene does not differ greatly from other depot antipsychotics (fluphenazine decanoate, fluphenazine enathate, perphenazine onanthat, pipotiazine undecylenate) with respect to treatment efficacy, response or tolerability. Outcomes suggest that fluspirilene does not differ significantly from oral antipsychotics or in different weekly regimens, although much cannot be inferred because of the shortage of trials.
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9807
Blood Brain Barrier+0.9713
Caco-2 permeable-0.68
P-glycoprotein substrateSubstrate0.7042
P-glycoprotein inhibitor IInhibitor0.9082
P-glycoprotein inhibitor IIInhibitor0.8257
Renal organic cation transporterInhibitor0.5978
CYP450 2C9 substrateNon-substrate0.835
CYP450 2D6 substrateNon-substrate0.5726
CYP450 3A4 substrateSubstrate0.645
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9209
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.6989
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7201
Ames testNon AMES toxic0.5428
CarcinogenicityNon-carcinogens0.8871
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6387 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8401
hERG inhibition (predictor II)Inhibitor0.9014
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Suspensionintramuscular10 mg
Suspensionintramuscular2 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point187.5-190Janssen, P.A.J.; U.S. Patent 3,238,216; March 1, 1966; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility10 mg/L (at 25 °C)MERCK INDEX (1996)
logP5.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00167 mg/mLALOGPS
logP5.18ALOGPS
logP5.78ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)11.99ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.58 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity135.27 m3·mol-1ChemAxon
Polarizability50.88 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Janssen, P.A.J.; U.S. Patent 3,238,216; March 1, 1966; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3238216
General ReferencesNot Available
External Links
ATC CodesN05AG01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluspirilene.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluspirilene.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluspirilene.
adipiplonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluspirilene.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluspirilene.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluspirilene.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluspirilene.
AmisulprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluspirilene.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluspirilene.
AmoxapineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amperozide.
AmphetamineFluspirilene may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.
ArticaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Azaperone.
AzelastineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluspirilene.
BaclofenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluspirilene.
BenzphetamineFluspirilene may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
BrimonidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.
BrompheniramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fluspirilene.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluspirilene.
ButacaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluspirilene.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluspirilene.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluspirilene.
CarbinoxamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluspirilene.
CarisoprodolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluspirilene.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluspirilene.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluspirilene.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluspirilene.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorphenamine.
ChlorphentermineFluspirilene may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluspirilene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluspirilene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluspirilene.
CitalopramThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluspirilene.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluspirilene.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluspirilene.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluspirilene.
CyclizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.
CyproheptadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.
DapoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluspirilene.
DesloratadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluspirilene.
DetomidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluspirilene.
DextroamphetamineFluspirilene may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluspirilene.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluspirilene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluspirilene.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluspirilene.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluspirilene.
DifenoxinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluspirilene.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluspirilene.
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluspirilene.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluspirilene.
DoramectinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluspirilene.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
DoxylamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Fluspirilene is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluspirilene.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluspirilene.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluspirilene.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluspirilene.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fluspirilene.
EfavirenzThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluspirilene.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluspirilene.
EntacaponeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluspirilene.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluspirilene.
EscitalopramThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluspirilene.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluspirilene.
EthanolFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluspirilene.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.
EthosuximideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluspirilene.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluspirilene.
EtidocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.
EtoperidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluspirilene.
EzogabineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluspirilene.
FenfluramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.
FexofenadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluspirilene.
FlunarizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluspirilene.
FluoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluspirilene.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fluspirilene is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluspirilene.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluspirilene.
GuanfacineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluspirilene.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluspirilene.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluspirilene.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fluspirilene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.
Hydroxyamphetamine hydrobromideFluspirilene may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
HydroxyzineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluspirilene.
IndalpineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluspirilene.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluspirilene.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluspirilene.
KetobemidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluspirilene.
LevocabastineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluspirilene.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluspirilene.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluspirilene.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluspirilene.
LisdexamfetamineFluspirilene may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Fluspirilene.
LithiumThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluspirilene.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluspirilene.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.
Lu AA21004The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluspirilene.
MeclizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluspirilene.
MelperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Melperone.
MephentermineFluspirilene may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.
MequitazineFluspirilene may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluspirilene.
MetaxaloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluspirilene.
MethamphetamineFluspirilene may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluspirilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluspirilene.
MethocarbamolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluspirilene.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluspirilene.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluspirilene.
MethsuximideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluspirilene.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.
MetyrosineFluspirilene may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluspirilene.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.
MilnacipranThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
MirtazapineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluspirilene.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluspirilene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.
NabiloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluspirilene.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluspirilene.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluspirilene.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluspirilene.
Nitrous oxideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluspirilene.
OlanzapineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluspirilene.
OpiumThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Opium.
OrphenadrineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluspirilene.
OsanetantThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluspirilene.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluspirilene.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluspirilene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluspirilene.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluspirilene.
ParaldehydeFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluspirilene.
ParoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluspirilene.
PerampanelThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluspirilene.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluspirilene.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenoxyethanol.
PhentermineFluspirilene may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluspirilene.
PipamperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.
PramipexoleFluspirilene may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluspirilene.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluspirilene.
PrimidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluspirilene.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluspirilene.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluspirilene.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluspirilene.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.
PropoxycaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluspirilene.
PSD502The risk or severity of adverse effects can be increased when Fluspirilene is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluspirilene.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluspirilene.
RamelteonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluspirilene.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluspirilene.
RomifidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Romifidine.
RopiniroleFluspirilene may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene.
RotigotineFluspirilene may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluspirilene.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluspirilene.
ScopolamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluspirilene.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluspirilene.
SertindoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluspirilene.
Sodium oxybateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.
SulpirideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluspirilene.
SuvorexantThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Fluspirilene.
TasimelteonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluspirilene.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluspirilene.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluspirilene.
TetracaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrodotoxin.
ThalidomideFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluspirilene.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluspirilene.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluspirilene.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluspirilene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.
TiagabineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluspirilene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluspirilene.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.
TrazodoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluspirilene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluspirilene.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluspirilene.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.
TriprolidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluspirilene.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluspirilene.
VigabatrinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.
ZiconotideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene.
ZolazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluspirilene.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluspirilene.
ZonisamideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluspirilene.
ZotepineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluspirilene.
Food Interactions
  • Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Wang SJ: Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. [PubMed:11842444 ]
  5. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Kenny BA, Fraser S, Kilpatrick AT, Spedding M: Selective antagonism of calcium channel activators by fluspirilene. Br J Pharmacol. 1990 Jun;100(2):211-6. [PubMed:1696149 ]
  2. Wang SJ: Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. [PubMed:11842444 ]
Comments
comments powered by Disqus
Drug created on September 27, 2007 07:56 / Updated on August 17, 2016 12:24